Search results: (10000)
News How Does Emicizumab Work in Obese Adults with Hemophilia A?
What is the annual bleeding rate and minimum concentration of emicizumab in obese adults with hemophilia A compared to non-obese individuals? Answers were sought by the authors of a pooled post hoc analysis of the HAVEN 1, 3, and 4 studies, the results of which were presented in the poster section of the 2021 ISTH virtual congress. Based on modeling, body weight appears to be an important predictor of emicizumab pharmacokinetics.
News Effects of Telmisartan on Vascular Endothelial Functions, Inflammation Parameters, and Insulin Resistance in Patients with CHD and DM
Patients with coronary heart disease (CHD) and diabetes mellitus (DM) often have dysfunctional vascular endothelium, increased inflammatory markers, and insulin resistance. The study presented below investigated the effects of telmisartan on these parameters associated with disease progression and worse prognosis.
News Effect of Romiplostim in Refractory ITP with Possibility of Maintaining Response Without Treatment – Case Report
This case report from the United States features an ideal therapeutic response to romiplostim in a patient with refractory immune thrombocytopenia (ITP). After several years of successful therapy, the medication could even be gradually discontinued while maintaining the therapeutic response.
News Impact of Dabigatran and Warfarin Treatment on the Risk of Acute Kidney Injury in Patients with Atrial Fibrillation
What clinical characteristics in patients with non-valvular atrial fibrillation may indicate a higher risk of acute kidney injury? Does the modality of anticoagulation therapy play a role in its incidence? These questions were the focus of an extensive retrospective study conducted in an Asian setting.
News When to Stop Dabigatran Anticoagulation Treatment Before Catheter Ablation in Patients with Atrial Fibrillation?
Catheter ablation is now a standard method of treating atrial fibrillation. Its most common complications are bleeding and thromboembolism. The aim of the analysis of 2 clinical studies presented below, whose conclusions were recently published, was to determine the optimal timing of stopping dabigatran anticoagulation treatment before this procedure.
News ADCT – a simple tool for self-diagnosis of patients with severe atopic dermatitis
Atopic dermatitis (AD) is a chronic inflammatory disease not only of childhood. It can negatively affect the quality of life despite being treatable. Control and management of the disease in different areas of life can be easily evaluated using the ADCT questionnaire.
News Results of Prophylactic Treatment of Severe von Willebrand Disease with Recombinant vWF
The phase III study cited below evaluated the efficacy and safety of 12-month prophylaxis with recombinant von Willebrand factor (rvWF) in 23 patients with severe von Willebrand disease (vWD), who had previously been treated either on-demand (during spontaneous bleeding episodes) or had been on prophylaxis with plasma-derived vWF (pdvWF).
News Benefits of Physical Activity for Individuals with Hemophilia – Recommendations of the MEMO Group
Regular physical activity can increase joint stability and function in individuals with hemophilia, reduce the risk of injury, improve quality of life, and have other positive effects. However, according to recent findings, a regular exercise program is not sufficiently emphasized in comprehensive hemophilia therapy. Therefore, a group of Italian experts has created a consensus summarizing current knowledge about the benefits of exercise for individuals with hemophilia and recommendations for physical activity.
News Long-term Clinical and Radiological Results of Implantation of Cementless Corail Stem
The Corail femoral stem with extensive hydroxyapatite coating for cementless implantation was introduced to the market several decades ago. The study cited below evaluated the clinical and radiological results of the implantation of this type of stem over a 20-year horizon in patients who underwent primary total hip arthroplasty.
News Antiviral and Anti-inflammatory Effects of Alpha-1-Antitrypsin in the Treatment of COVID-19
Human alpha-1-antitrypsin (AAT) is a circulating blood glycoprotein that has been used for decades in the treatment of patients with AAT deficiency, lung damage, and emphysema, helping to prevent acute lung injury. Recently, it has been found that AAT also mitigates the course of COVID-19 disease by hindering the entry of the SARS-CoV-2 coronavirus into host cells. This dual antiviral and anti-inflammatory action makes AAT an excellent candidate for COVID-19 treatment.
News Effect of Trifluridine/Tipiracil Combination Depending on Patient Prognosis
The results of the RECOURSE clinical study were published in 2015 and became an important basis for the approval of the trifluridine/tipiracil combination in the treatment of metastatic colorectal cancer (mCRC). The data obtained in this study were also subjected to several post-hoc analyses. One of these recently brought information on how patient prognosis affects the clinical outcomes of this treatment.
News How Common is Alpha-1 Antitrypsin Deficiency?
What is the prevalence of alpha-1 antitrypsin deficiency (AATD)? What comorbidities are associated with it? Are healthcare costs for these patients higher compared to patients with unrelated obstructive lung diseases? Awareness of AATD is low and prevalence data are only indicative. The authors of a study published in the European Respiratory Journal aimed to map this disease in a population of 4 million German insured individuals.
News Deep stimulation of the globus pallidus improved clinical symptoms in a patient with refractory parkinsonism and genetic mutation
The authors of the presented work studied the effects of deep brain stimulation (DBS) in a patient with Parkinson's disease with a genetic mutation that manifests in early adulthood.
News Laboratory Safety of Dupilumab Treatment in Children with Atopic Dermatitis Aged 6 Months to 6 Years
Previous clinical studies in children aged 6–12 years with moderate-to-severe atopic dermatitis have demonstrated laboratory safety during dupilumab treatment. The randomized study presented below supplements the data for the age group from 6 months to 6 years.
News Do real-world clinical practice data confirm the results of cenobamate treatment in the clinical program?
A recent study by Spanish authors presents the largest dataset of patients with published cenobamate treatment results under prolonged observation in real-world clinical practice at the time of article publication. Data are derived from an expanded access program for a population with highly drug-resistant focal seizures.
News Safety of aPCC in Real Practice – Results of the BAHAS Project
What are the experiences with activated prothrombin complex concentrate (aPCC) in controlling bleeding or preventing its recurrence in acquired hemophilia A? The BAHAS project from Spanish real practice offers answers.
News Thromboprophylaxis in Generalized Pancreatic Cancer
Pancreatic adenocarcinoma is one of the tumors with the highest risk of developing thromboembolic disease (TED). Although anticoagulant treatment reduces the risk of TED, its positive effect on the overall survival of patients has not yet been proven.
News Does Emicizumab Change Routine Clinical Practice?
With the increasing number of patients with hemophilia A being treated with emicizumab, the question arises whether its use in any way changes established clinical practice. A team of American authors sought answers based on a survey conducted among the treating physicians of these patients. The findings were presented at the 13th Annual EAHAD Congress, which took place at the beginning of February in The Hague, Netherlands.
News Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
The aging population of individuals with hemophilia brings new experiences and challenges, leading to the search for the safest and most effective treatments and prevention strategies for diseases typical of older age, particularly cardiovascular and cerebrovascular diseases. It is important to recognize that these complications pose a real risk for individuals with hemophilia, a risk that has thus far been somewhat underestimated.
News Venetostart – The First Comprehensive Mobile Application with Practical Information for Venetoclax Treatment
Abbvie has developed the comprehensive mobile application Venetostart with practical information needed in clinical practice for administering venetoclax (Venclyxto), which is indicated for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
News Impact of Initial RAAS Inhibitor on Hospitalization Risk in HFrEF Patients
Inhibition of the renin-angiotensin-aldosterone system (RAAS) is considered a key step in the treatment of heart failure with reduced ejection fraction (HFrEF). The preferred medication currently is the angiotensin II receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan, which has shown to improve the prognosis of patients with HFrEF. A recently published study compared the initiation of ARNI or angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) in patients with HFrEF who were not previously treated with a RAAS inhibitor in real-world practice.
News ERS 2023: Erdostein and its Metabolite Met-1 Modulate Innate Immunity and Oxidative Stress in SARS-CoV-2 Infection
As part of the September congress of the European Respiratory Society (ERS 2023), the issue of COVID-19 was also addressed. Among the late-breaking messages was an e-poster by experts from the University of Milan, who in their study examined the potential of erdosteine and its active metabolite Met-1 in treating this disease, based on research into its application to cells infected with SARS-CoV-2.
News ITP with Severe Hemorrhagic Manifestations Associated with COVID-19 – Case Study
There can be numerous causes of newly acquired immune thrombocytopenia (ITP), often being idiopathic. Severe COVID-19 can be associated with ITP manifestations where the standard first-line treatment may not be effective. In life-threatening bleeding situations, adding romiplostim has proven effective, as illustrated by the following case study from authors in Montreal, Canada.
News Focused on the Effect of Teriflunomide on Lymphocyte Subpopulations
Teriflunomide is a common choice for long-term therapy of the relapsing-remitting form of multiple sclerosis. The use of this immunomodulatory agent results in a decrease in lymphocyte numbers. Its effect on different lymphocyte subpopulations, however, has not been fully elucidated. Italian authors of a study published in the journal Neurology: Neuroimmunology and Neuroinflammation attempted to refine this knowledge.